Sign In
Buy PPCB
$1.77
-0.0400 (-2.21%)
At Close: Jun 02, 2026
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
11:00pm, Thursday, 14'th Aug 2025
MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments fo
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Show with Joel Block, “Your Advantage Play®, In Search of the Ultimate Competitive Advantage” MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or t
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
08:56am, Thursday, 13'th Jul 2023
Reader interest above 93% of published research articles over the past year MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a bi
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
04:00pm, Wednesday, 05'th Jul 2023
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma Provides Shareholder Update
11:49pm, Thursday, 22'nd Jun 2023
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma Announces Reverse Stock Split
10:53pm, Monday, 22'nd May 2023
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
01:48am, Friday, 17'th Mar 2023
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
09:02am, Wednesday, 26'th Oct 2022
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 – 17
09:12am, Wednesday, 12'th Oct 2022
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment
03:19am, Friday, 09'th Sep 2022
MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suff
Propanc Biopharma to Present at the 2019 BIO CEO & Investor Conference
09:00am, Tuesday, 29'th Jan 2019
MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc”), a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for ca
